CA2073856C - Glp-1 analogs useful for diabetes treatment - Google Patents

Glp-1 analogs useful for diabetes treatment Download PDF

Info

Publication number
CA2073856C
CA2073856C CA002073856A CA2073856A CA2073856C CA 2073856 C CA2073856 C CA 2073856C CA 002073856 A CA002073856 A CA 002073856A CA 2073856 A CA2073856 A CA 2073856A CA 2073856 C CA2073856 C CA 2073856C
Authority
CA
Canada
Prior art keywords
glp
amino acid
peptide
modification
paragraph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002073856A
Other languages
English (en)
French (fr)
Other versions
CA2073856A1 (en
Inventor
Douglas I. Buckley
Joel Habener
Joanne B. Mallory
Svetlana Mojsov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Scios LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2073856A1 publication Critical patent/CA2073856A1/en
Application granted granted Critical
Publication of CA2073856C publication Critical patent/CA2073856C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CA002073856A 1990-01-24 1991-01-24 Glp-1 analogs useful for diabetes treatment Expired - Lifetime CA2073856C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46873690A 1990-01-24 1990-01-24
US468,736 1990-01-24
PCT/US1991/000500 WO1991011457A1 (en) 1990-01-24 1991-01-24 Glp-1 analogs useful for diabetes treatment

Publications (2)

Publication Number Publication Date
CA2073856A1 CA2073856A1 (en) 1991-07-25
CA2073856C true CA2073856C (en) 2002-12-03

Family

ID=23861028

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002073856A Expired - Lifetime CA2073856C (en) 1990-01-24 1991-01-24 Glp-1 analogs useful for diabetes treatment

Country Status (8)

Country Link
EP (1) EP0512042B1 (https=)
JP (5) JP3262329B2 (https=)
AT (1) ATE164852T1 (https=)
CA (1) CA2073856C (https=)
DE (1) DE69129226T2 (https=)
DK (1) DK0512042T3 (https=)
ES (1) ES2113879T3 (https=)
WO (1) WO1991011457A1 (https=)

Families Citing this family (241)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
USRE37302E1 (en) * 1992-03-19 2001-07-31 Novo Nordisk A/S Peptide
SK155694A3 (en) * 1992-06-15 1995-05-10 Pfizer Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
EP0658568A1 (en) * 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
DK144093D0 (https=) * 1993-12-23 1993-12-23 Novo Nordisk As
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
WO1996036883A1 (en) * 1995-05-17 1996-11-21 Novo Nordisk A/S Immunoassay for glucagon like protein 1 (glp-1) in plasma
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
DE19616486C5 (de) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
IL128332A0 (en) * 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP1566180A3 (en) * 1996-08-30 2007-08-08 Eli Lilly & Company Use of GLP-1 or Analogs in Treatment of Myocardial Infarction
EP0929576A1 (en) * 1996-08-30 1999-07-21 Novo Nordisk A/S Glp-2 derivatives
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
EP0996459B1 (en) 1997-01-07 2005-09-21 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
DE59811840D1 (de) * 1997-09-12 2004-09-23 Pharis Biotec Gmbh Zusammensetzung zur therapie von diabetes mellitus und fettsucht
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
WO1999025727A2 (en) 1997-11-14 1999-05-27 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
JP2001525371A (ja) * 1997-12-05 2001-12-11 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１製剤
AU766219B2 (en) 1998-02-02 2003-10-09 1149336 Ontario Inc. Method of regulating glucose metabolism, and reagents related thereto
EP1061946B1 (en) * 1998-02-27 2004-04-28 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
FR2777283B1 (fr) * 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JPH11328947A (ja) 1998-05-18 1999-11-30 Nec Corp 大規模ｆｉｆｏ回路
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
EP1666054A1 (en) 1998-08-28 2006-06-07 Eli Lilly & Company Method for administering insulinotropic peptides
CN1317967A (zh) 1998-09-17 2001-10-17 伊莱利利公司 蛋白质制剂
US6461834B1 (en) 1998-11-06 2002-10-08 Bionebraska, Inc. Clostripain catalyzed amidation of peptides
JP2002538081A (ja) 1998-12-07 2002-11-12 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１の類似体
DE69922043T2 (de) * 1998-12-07 2005-11-24 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Glp-1 analoge
EP1359159A3 (en) * 1998-12-07 2004-07-21 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues of GLP-1
US7425541B2 (en) * 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
SI1140148T1 (sl) 1998-12-22 2006-04-30 Lilly Co Eli Stabilna formulacija raztopine glukagonu podobnega peptida-1
US6927214B1 (en) 1999-01-15 2005-08-09 Novo Nordisk A/S Non-peptide GLP-1 agonists
WO2000055203A1 (en) 1999-03-15 2000-09-21 Novo Nordisk A/S Ion exchange chromatographic separation of glp-1 and related peptides
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
CA2363712C (en) 1999-05-17 2011-05-10 Conjuchem Inc. Long lasting insulinotropic peptides
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
DE19940130A1 (de) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
JP2003514532A (ja) * 1999-11-19 2003-04-22 トランスカーヨティック セラピーズ インコーポレイテッド 生成物の産生量を最適化するための核酸構築体
PT1741446E (pt) 2000-01-21 2008-05-09 Novartis Pharma Ag Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos
JP2003525908A (ja) 2000-03-08 2003-09-02 ノボ ノルディスク アクティーゼルスカブ 血清脂質の低下
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
ATE424413T1 (de) * 2000-06-16 2009-03-15 Lilly Co Eli Analoge des glucagon-ähnlichen peptids-1
AR033390A1 (es) 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
ES2310192T3 (es) 2000-09-18 2009-01-01 Sanos Bioscience A/S Uso de peptidos glp-2.
US7132104B1 (en) 2000-10-27 2006-11-07 Probiodrug Ag Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
CA2430934C (en) 2000-12-01 2011-06-21 Takeda Chemical Industries, Ltd. A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
EP1351984A2 (en) 2000-12-13 2003-10-15 Eli Lilly And Company Amidated glucagon-like peptide-1
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
CN1162446C (zh) 2001-05-10 2004-08-18 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
DE10150203A1 (de) 2001-10-12 2003-04-17 Probiodrug Ag Peptidylketone als Inhibitoren der DPIV
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
CA2458371A1 (en) 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
US6864069B2 (en) 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
CN1332711C (zh) 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
JP2005527504A (ja) 2002-02-28 2005-09-15 プロシディオン・リミテッド グルタミニルを基礎するｄｐｉｖ阻害剤
EP1525219B1 (en) 2002-07-04 2009-05-27 Zealand Pharma A/S Glp-1 and methods for treating diabetes
JP2006501820A (ja) * 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
CA2500021A1 (en) 2002-09-25 2004-04-08 Theratechnologies Inc. Modified glp-1 peptides with increased biological potency
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
WO2004035624A2 (en) 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102134577A (zh) * 2003-03-28 2011-07-27 独立行政法人农业生物资源研究所 高产重组蛋白的植物贮藏器官的生产方法以及新型重组蛋白
JP4806628B2 (ja) 2003-05-05 2011-11-02 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤
KR20110059664A (ko) 2003-05-05 2011-06-02 프로비오드룩 아게 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7094800B2 (en) 2003-07-25 2006-08-22 Sanofi-Aventis Deutschland Gmbh Cyanopyrrolidides, process for their preparation and their use as medicaments
US7008957B2 (en) 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7094794B2 (en) 2003-07-28 2006-08-22 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10335092B3 (de) 2003-08-01 2005-02-03 Aventis Pharma Deutschland Gmbh Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
EP1664108B1 (en) 2003-08-21 2009-10-14 Novo Nordisk A/S Separation of polypeptides comprising a racemized amino acid
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
BRPI0415409A (pt) 2003-10-15 2006-12-05 Probiodrug Ag uso de efetuadores de ciclases de glutaminila e glutamato
TR201906789T4 (tr) 2003-11-20 2019-05-21 Novo Nordisk As Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları.
ATE498404T1 (de) 2003-12-09 2011-03-15 Novo Nordisk As Regulierung der nahrungspräferenz mit glp-1- agonisten
EP1711523B1 (en) 2003-12-16 2012-10-10 Ipsen Pharma Analogues of glp-1
US7521527B2 (en) 2003-12-16 2009-04-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. GLP-1 pharmaceutical compositions
MXPA06006745A (es) 2003-12-18 2006-08-18 Novo Nordisk As Compuestos glp-1 novedosos.
US7538185B2 (en) 2004-01-08 2009-05-26 Theratechnologies Inc. Glucagon-like peptide-1 analogs with long duration of action
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP1718665B1 (en) 2004-02-11 2013-04-10 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
JP2008507280A (ja) 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
CA2589800A1 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
JP5755398B2 (ja) 2005-03-18 2015-07-29 ノヴォ ノルディスク アー／エス 伸長されたｇｌｐ−１化合物
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2006110887A2 (en) 2005-04-11 2006-10-19 Amylin Pharmaceuticals, Inc Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
EP1889618A4 (en) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd Combined drug for treating diabetes
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
PL1931350T5 (pl) 2005-09-14 2021-11-15 Takeda Pharmaceutical Company Limited Podanie inhibitorów dipeptydylo-peptydazy
GEP20135838B (en) 2005-09-14 2013-06-10 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors usage at diabetes treatment
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
PL1767545T3 (pl) 2005-09-22 2010-04-30 Biocompatibles Uk Ltd Polipeptydy fuzyjne GLP-1 (glukagonopodobny peptyd-1) o zwiększonej odporności na peptydazy
EP1943275B1 (en) * 2005-11-01 2010-06-16 Activotec SPP Limited Insulinotropic compounds and uses thereof
EP2570133B1 (en) 2005-11-07 2016-03-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
CN100374462C (zh) * 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 截短胰高血糖素样肽1(sGLP-1)、制法及其应用
JPWO2007063907A1 (ja) * 2005-11-30 2009-05-07 塩野義製薬株式会社 ペプチド糖鎖付加体およびそれを有効成分とする医薬
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
ES2495741T3 (es) 2006-04-20 2014-09-17 Amgen, Inc Compuestos de GLP-1
RU2008147398A (ru) * 2006-05-02 2010-06-10 Актогеникс Н.В. (Be) Доставка пептидов, связанных с ожирением, через кишечник посредством микроорганизмов
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
RU2350324C1 (ru) * 2007-08-02 2009-03-27 Закрытое акционерное общество "Биологические исследования и системы" Способ лечения сахарного диабета 2 типа, осложненного полиневропатией
WO2009030774A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US8980830B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
AU2009210570B2 (en) 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
KR20100132535A (ko) 2008-03-31 2010-12-17 글락소 그룹 리미티드 약물 융합체 및 컨주게이트
DK2300035T3 (en) 2008-06-17 2015-11-16 Univ Indiana Res & Tech Corp Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
EP2300037B1 (en) 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
WO2010054326A2 (en) 2008-11-07 2010-05-14 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (glp-1)
JP5756407B2 (ja) 2008-12-08 2015-07-29 ノヴォ ノルディスク アー／エス ポリペプチドの向流精製
US8748377B2 (en) * 2008-12-10 2014-06-10 Glaxosmithkline Llc Pharmaceutical compositions
CN102325539A (zh) * 2008-12-19 2012-01-18 印第安纳大学研究及科技有限公司 基于酰胺的胰高血糖素超家族肽前药
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
EP2411054A2 (en) 2009-03-27 2012-02-01 Glaxo Group Limited Drug fusions and conjugates
HRP20140371T1 (hr) 2009-05-15 2014-05-23 Novartis Ag Arilpiridini kao inhibitori sinteze aldosterona
WO2010130773A2 (en) 2009-05-15 2010-11-18 Novartis Ag Benzoxazolone derivatives as aldosterone symthase inhibitors
CN103896796B (zh) 2009-05-28 2016-04-27 诺华股份有限公司 作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物
EP2435402B1 (en) 2009-05-28 2016-04-13 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
JP6086528B2 (ja) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有する成長ホルモン
MX2012003939A (es) 2009-09-30 2012-07-30 Glaxo Group Ltd Fusiones y conjugados de farmaco.
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
US8519134B2 (en) 2009-11-17 2013-08-27 Novartis Ag Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
ES2472446T3 (es) 2009-11-30 2014-07-01 Novartis Ag Derivados de imidazol como inhibidores de aldosterona sintasa
EP2512518A1 (en) * 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
CN118767117A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
PL2531501T3 (pl) 2010-02-03 2014-05-30 Takeda Pharmaceuticals Co Inhibitory kinazy 1 regulującej sygnał apoptotyczny
US9168288B2 (en) 2010-04-09 2015-10-27 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
EA023925B1 (ru) 2010-04-27 2016-07-29 Зилэнд Фарма А/С Пептидные конъюгаты агонистов рецептора glp-1 и их применение
WO2011136361A1 (ja) 2010-04-30 2011-11-03 株式会社 三和化学研究所 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
WO2011143788A1 (en) 2010-05-17 2011-11-24 Zhejiang Beta Pharma Inc. Novel glucagon like peptide analogs, composition, and method of use
JP5912112B2 (ja) 2010-06-24 2016-04-27 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ アミド系インスリンプロドラッグ
RU2580317C2 (ru) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
WO2012054861A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Glp-1 polymer conjugates having a releasable linkage
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
US9040481B2 (en) 2010-11-02 2015-05-26 The General Hospital Corporation Methods for treating steatotic disease
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
WO2012121302A1 (ja) 2011-03-08 2012-09-13 株式会社 三和化学研究所 分析方法
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
RU2602601C2 (ru) 2011-04-12 2016-11-20 Ново Нордиск А/С Дважды ацилированные производные glp-1
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
RS56173B1 (sr) 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
WO2013006692A2 (en) 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
WO2013060887A1 (en) * 2011-10-28 2013-05-02 Pharis Biotec Gmbh A polypeptide for the protection against heart ischemia-reperfusion injury
MX2014005351A (es) 2011-11-03 2014-05-28 Zealand Pharma As Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
WO2013083826A2 (en) * 2011-12-09 2013-06-13 Novo Nordisk A/S Glp-1 agonists
CN104203266B (zh) 2012-03-22 2017-12-26 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
JP2015523332A (ja) 2012-05-16 2015-08-13 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 経口投与のためのポリペプチド搭載ｐｏｃａナノ粒子
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
CA2877358A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
EP2873422A4 (en) 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
AU2013295035B2 (en) 2012-07-23 2017-08-03 Zealand Pharma A/S Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CU24330B1 (es) 2013-02-14 2018-03-13 Novartis Ag Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
JP6672140B2 (ja) 2013-05-02 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１化合物の経口投薬
SG11201508469YA (en) 2013-05-02 2015-11-27 Glaxosmithkline Ip Dev Ltd Therapeutic peptides
CN105705167A (zh) 2013-07-25 2016-06-22 诺华股份有限公司 合成的apelin多肽的生物缀合物
MX2016001020A (es) 2013-07-25 2016-08-03 Novartis Ag Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca.
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2015055801A1 (en) 2013-10-17 2015-04-23 Zealand Pharma A/S Acylated glucagon analogues
MX2016005556A (es) 2013-11-06 2016-07-15 Zealand Pharma As Compuestos agonistas duales de gip-glp-1 y procedimientos.
AU2014345570B2 (en) 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
CR20170338A (es) 2015-01-23 2017-09-12 Novartis Ag Conjugados de ácidos grasos y apelina sintética con mayor vida media
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
EP3463424A1 (en) * 2016-06-02 2019-04-10 Indiana University Research & Technology Corporation Glucagon-like peptide-1-t3 conjugates
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
AU2017371516C1 (en) 2016-12-09 2021-09-02 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
CN109836504B (zh) * 2017-11-24 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
US20230089867A1 (en) 2018-11-27 2023-03-23 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
JP7657151B2 (ja) 2018-11-27 2025-04-04 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド
GB201917723D0 (en) 2019-12-04 2020-01-15 Nv Rose Llc Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
CN114729060B (zh) 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
CN114958883B (zh) * 2022-04-12 2023-01-31 北京惠之衡生物科技有限公司 一种表达glp-1类似物的重组工程菌及其构建方法
WO2024106505A1 (ja) * 2022-11-16 2024-05-23 株式会社ポル・メド・テック 豚臓器又はその由来物を含む移植材の製造方法
KR20260015867A (ko) 2023-05-24 2026-02-03 노파르티스 아게 질환 또는 장애 치료용 나프티리디논 유도체
CN119569847A (zh) * 2024-12-03 2025-03-07 中国科学院上海有机化学研究所 Glp-1变体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE110083T1 (de) * 1986-05-05 1994-09-15 Gen Hospital Corp Insulinotropes hormon.

Also Published As

Publication number Publication date
JP2001151798A (ja) 2001-06-05
WO1991011457A1 (en) 1991-08-08
DK0512042T3 (da) 1998-05-11
JP2005132848A (ja) 2005-05-26
DE69129226D1 (de) 1998-05-14
DE69129226T2 (de) 1998-07-30
ATE164852T1 (de) 1998-04-15
JP2003192698A (ja) 2003-07-09
EP0512042A4 (en) 1993-02-17
JPH05506427A (ja) 1993-09-22
CA2073856A1 (en) 1991-07-25
EP0512042A1 (en) 1992-11-11
JP3262329B2 (ja) 2002-03-04
JP2004196825A (ja) 2004-07-15
ES2113879T3 (es) 1998-05-16
EP0512042B1 (en) 1998-04-08

Similar Documents

Publication Publication Date Title
CA2073856C (en) Glp-1 analogs useful for diabetes treatment
US5545618A (en) GLP-1 analogs useful for diabetes treatment
KR102444783B1 (ko) 인크레틴 유사체 및 그의 용도
CA2455963C (en) Glp-1, exendin-4, peptide analogs and uses thereof
CA2352573C (en) Glp-1 analogues
US7875587B2 (en) Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US20100256056A1 (en) Analogues of exendin-4 and exendin-3
US20070173455A1 (en) Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
CA2335341A1 (en) Peptide analogues of pacap
JPH11505521A (ja) グルカゴン様ペプチド−２、ならびにその治療への使用
JP2016183177A (ja) 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
JPH08245696A (ja) グルカゴン様インスリン親和性ペプチド類似体及び組成物
CA2367856A1 (en) Analogs of gastric inhibitory peptide and their use for treatment of diabetes
AU2005217198A1 (en) Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
CZ297381B6 (cs) Somatostatinové peptidy a farmaceutické prostredky s jejich obsahem
WO1998024464A1 (en) Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
JP2837352B2 (ja) 胃腸運動活性を抑制するモチリン類似ポリペプチド
RU2557301C2 (ru) Новые аналоги глюкагон-подобного пептида, композиция и способ применения
EP3530671A2 (en) Gip peptide analogues
DE69938548T2 (de) Pth2 rezeptor selektive verbindungen
AU669636B2 (en) Amylin antagonists and agonists
NO330706B1 (no) Farmasøytisk sammensetning som omfatter somatostatinanalog og vinsyre samt anvendelse derav
Hall et al. Somatostatin: a historical perspective
AU2012202081B2 (en) GLP-1 Exendin-4 peptide analogs and uses thereof
Pless From Somatostatin to Sandostatin [R]: History and Chemistry

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry